CMS is proposing to limit coverage of beta amyloid positron emission tomography to help diagnosis dementia and neurodegenerative disease only to patients enrolled in qualifying clinical trials. The decision is a setback for Eli Lilly & Co. and its PET imaging agent Amyvid.
Last July, Lilly requested that CMS reconsider its national non-coverage policy for beta amyloid PET scans. CMS initiated a national coverage analysis on the topic in October. (See Also see...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?